Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Core Insights - Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab, enhancing understanding of its immune modulation effects [1][4]. Group 1: Study Findings - The study identified gene expression changes starting three months after intranasal dosing of foralumab, with key findings related to antigen presentation and interferon responses [2]. - Single-cell RNA sequencing revealed gene expression changes associated with nasal foralumab, correlating with reduced microglial brain inflammation as measured by PET scans [3]. Group 2: Clinical Implications - The findings indicate potential for nasal foralumab in modulating critical immune pathways, paving the way for personalized treatment strategies for MS [4]. - Clinical stabilization and microglial PET findings support the biological effects of nasal foralumab, establishing a framework for monitoring treatment efficacy in future trials [4]. Group 3: Product Information - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally, with positive outcomes observed in 10 patients with na-SPMS [5]. - The FDA has allowed enrollment of an additional 20 patients in the Expanded Access Program, indicating ongoing interest and potential for further clinical exploration [5]. Group 4: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, with a lead candidate of intranasal foralumab showing a favorable safety profile [9]. - The company's approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods, with several patents pending for its technology [9].